Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04222972
Recruitment Status : Recruiting
First Posted : January 10, 2020
Last Update Posted : October 30, 2020
Sponsor:
Information provided by (Responsible Party):
Blueprint Medicines Corporation

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : December 2024